28 results about "Sarcoidosis" patented technology

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

Described are methods for treating patients with pulmonary hypertension associated with sarcoidosis (PH-SARC) using inhaled nitric oxide (iNO).

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof. In some embodiments, an outcome of the methods of the present technology is increased relative to the same method comprising use of a corticosteroid.

The disclosure provides a method of treating sarcoidosis, the method comprising administering a GHRH antagonist to mammalian subject in need thereof.

There is provided herein a compound of formula I,wherein R1, R2, R3 Y1, Y2, Y3, Y4, R4, R5 and R6 are as defined herein, which compounds are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

There is provided herein a compound of formula I, wherein R1, R2, R3 Y1, Y2, Y3, Y4, R4, R5 and R6 are as defined herein, which compounds are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

Sarcoidosis is a multisystem disease characterized by granulomatous inflammation in affected organs. The present invention discloses kits and a system for a blood test using mycobacterial catalase-peroxidase that has a high positive predictive value for confirming a diagnosis of sarcoidosis.

The pharmaceutical compound or the pharmaceutically acceptable salt thereof is used for preventing or treating the following diseases by simultaneously inhibiting autotaxin (ATX) and activating peroxisome proliferator-activated receptor gamma (PPAR gamma): a) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases, and b) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases; the present invention relates to a pharmaceutical composition for treating hepatitis, such as various hepatitis and / or non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) and / or cirrhosis, where said ILD may be a primary disease, preferably idiopathic pulmonary fibrosis and / or sarcoidosis and / or interstitial pneumonia, or said ILD is a complication associated with an autoimmune and / or inflammatory and / or metabolic disease, or a pharmaceutical composition comprising said ILD. Preferably rheumatoid arthritis ILD and / or scleroderma ILD and / or myositis ILD and / or diabetes ILD and / or cardiovascular disease ILD; and / or b) inflammatory and / or autoimmune diseases, preferably rheumatoid arthritis and / or scleroderma; and / or c) cancer, in particular lung and / or hepatocellular carcinoma and / or pancreatic cancer and / or glioblastoma and / or neuroblastoma; and / or d) a metabolic disease, in particular diabetes mellitus type 1 and / or diabetes mellitus type 2 and / or obesity, having a formula selected from the group consisting of formulae (A), (B), (C), (D), (E), (F), (G) and (H).

The invention provides a traditional Chinese medicine composition for treating benign nodules and a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 12 to 18 parts of bistort rhizome, 24 to 36 parts of hairyvein agrimony, 9.6 to 14.4 parts of pseudobulbus cremastrae seu pleiones, 16 to 24 parts of fructus forsythiae, 12 to 18 parts of platycodon grandiflorum, 16 to 24 parts of thunberg fritillary bulb and 14.4 to 21.6 parts of spanishneedles herb. The invention further provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition aims at the core pathogenesis of qi stagnation and blood stasis syndromes of sarcoidosis, namely phlegm and blood stasis, and heat from depression to qi, has the effects of clearing heat, eliminating stagnation, reducing phlegm, removing blood stasis, tonifying qi and strengthening the body resistance, is used for treating benign nodules of lung, thyroid or mammary gland, achieves the effect of treating different diseases at the same time, and has the advantages of being definite in curative effect, small in side effect and capable of preventing relapse.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The application provides a traditional Chinese medicine composition for treating benign nodules and a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from raw medicinal materials in the following weight ratio: Bistorta 12-18 parts, Agrimonia pilosa 24-36 parts, Laetiporus 9.6-14.4 parts, Forsythia 16-24 parts, Platycodon 12-18 parts, Fritillaria thunbergii Miq. 16-24 parts and Begonia fimbristipula 14.4-21.6 parts. The application also provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition aims at the core pathogenesis of phlegm and blood stasis syndrome of tuberculosic disease, has the effects of clearing heat, resolving nodules, resolving phlegm and removing blood stasis, and has the effects of tonifying qi and supporting healthy energy, is used for treating benign nodules of the lung, thyroid or breast, achieves the effect of treating different diseases in the same way, and has the advantages of accurate curative effect, small side effect and prevention of recurrence.

At present, the treatment methods for sarcoidosis include operative treatment, radiochemical treatment and drug treatment (including traditional Chinese medicine decoction). Wherein the operative treatment has a good curative effect on early-stage patients, but the treatment cost is high; the treatment effect on advanced patients is poor; traditional Chinese medicine decoction is long in conditioning time and slow in treatment speed. In order to better treat nodule diseases and overcome the defects in the prior art, the invention provides the liqueur for treating nodules, which can effectively treat various nodules, and has the advantages of simultaneous treatment of medicine and food, small side effect, low cost and good curative effect.

Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof.

The disclosure relates to a sarcoidosis animal model and methods of inducing sarcoidosis in an animal. The disclosure also relates to methods of producing an in vitro granuloma, and methods of using the sarcoidosis animal model. Disclosed herein are animals comprising one or more granulomas, wherein the one or more granulomas comprise Mycobacterium abscessus cell wall microparticles.

Provided herein are compositions and methods for treating neuroinflammatory diseases and conditions, the neuroinflammatory diseases and conditions include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), optic neuromyelitis (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), vascular dementia (VAD), anti-oligodendroglia glycoprotein antibody disease (MOGAD), and the like. Transverse myelitis (TM), autoimmune encephalitis (AE), acute disseminated encephalomyelitis (ADEM), chronic meningitis (CM), central nervous system (CNS) vasculitis, hashimoto encephalitis (HE), neurosarcoidosis (NS), multi-system atrophy (MSA), migraine, chemotherapy-induced pain or dementia-related pain.

The present invention relates to a pharmaceutical compound or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of the following conditions, wherein the pharmaceutical compound or a pharmaceutically acceptable salt thereof is characterized in that it simultaneously inhibits autotaxin (ATX) and agonizes PPARγ, and has a chemical formula selected from the group consisting of formulas (A), (B), (C), (D), (E), (F), (G), and (H): a) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases such as all types of hepatitis and / or non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) and / or cirrhosis, where the ILD is a primary disease, preferably idiopathic pulmonary fibrosis and / or sarcoidosis and / or interstitial pneumonia, or where the ILD is associated with an autoimmune and / or inflammatory and / or metabolic disease, preferably rheumatoid arthritis-ILD ​​and / or scleroderma-ILD and / or myositis-ILD ​​and / or diabetes-ILD ​​and / or cardiovascular disease-ILD combination, and / or b) an inflammatory and / or autoimmune disease, preferably rheumatoid arthritis and / or scleroderma, and / or c) cancer, in particular lung cancer and / or hepatocellular carcinoma and / or pancreatic cancer and / or glioblastoma and / or neuroblastoma, and / or d) metabolic diseases, in particular type 1 diabetes and / or type 2 diabetes and / or obesity [Formula 1] TIFF2026503883000014.tif94126

The invention discloses a nodule pathology correlation depth prediction system, and belongs to the technical field of medical image analysis and artificial intelligence. Comprising an image feature extraction module, a clinical information extraction module, a blood marker extraction module, a modal fusion module, a multi-task prediction module, a confidence evaluation module, a feedback optimization module and a visual report generation module. The core innovation lies in that the modal fusion module dynamically distributes the fusion weight of each modal by calculating a correlation matrix among image features, clinical features and blood features to realize adaptive weighted fusion, and the confidence coefficient evaluation module realizes adaptive weighted fusion by segmenting three dimensions of quality evaluation, immune verification and model cross validation. A feedback optimization module triggers re-optimization of a fusion strategy according to the confidence score when the confidence score is lower than a preset threshold value, a closed-loop regulation mechanism is formed, and the nodule histological type, the gene mutation state and the immune phenotype can be predicted at the same time.

The invention discloses a pathological differential diagnosis method, system and equipment for tuberculosis and sarcoidosis in lung and lymph nodes, and relates to the field of pathological identification. The method comprises the following steps: cutting a tissue area sub-image of a lung or lymph node in a digital slice of the lung or lymph node of a patient; performing non-overlapping partitioning on the tissue area sub-image, and filtering to obtain a plurality of pathological blocks; performing feature coding on each pathological block by using a pre-trained large pathological model, and retaining block feature vectors identified as abnormal tissues by using a trained multi-layer perceptron model; converting the cut block feature vectors of all the retained abnormal tissues into a standardized cut block feature sequence, splicing the standardized cut block feature sequence with a CLS token to serve as input data, and performing binary classification on tuberculosis and sarcoidosis of lung or lymph nodes by using a trained Transform architecture-based full-slice image level classification model to obtain a pathological differential diagnosis result. The accuracy and efficiency of pathological diagnosis can be improved.

This invention discloses a phase-locked monitoring and early warning system for bovine nodular dermatitis based on digital twins, relating to the fields of artificial intelligence and bovine nodular disease monitoring, early warning, and forecasting technologies. It includes a Culicoides midge blood meal detection sentinel device, a polarized structured light dual-image acquisition device, a phase-locked disease progression digital twin engine, an insect-borne reverse control execution device, data storage nodes, and communication nodes. The sentinel device outputs zonal propagation pressure curves, hot zone migration speeds, and time-period peak windows; the dual-image acquisition device triggers acquisition within the peak window and outputs three-dimensional deformation reconstruction results and polarization reflection difference features; the digital twin engine, based on propagation phase estimation, vital sign phase estimation, hysteresis constraint compilation, and phase consistency gating, outputs individual-level disease progression stage status, early warning and forecast time windows, and zonal-level early warning levels, and generates control action sequences and targeted sampling plans; counterfactual trajectory generation and parameter updates achieve consistency comparison and trigger resampling and control strategy reconfiguration.

The present invention provides novel pharmaceutical compounds of formula I, wherein R 1 , R 2 , R 3 , R 4 , R 5 , n and Z are as defined herein, which are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases such as idiopathic pulmonary fibrosis and sarcoidosis.

According to the invention, a pharmaceutical dosage form suitable for peroral administration into the gastrointestinal tract is provided. This dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, mixed with a mixture of carrier particles having a weight- and / or volume-based mean diameter and / or structural / particle density similar to the weight- and / or volume-based mean diameter and / or structural / particle density of the solid C21 particles, and a glide. This composition is contained within a capsule suitable for peroral administration. The preferred carrier particles have a weight- and / or volume-based mean diameter of less than approximately 100 µm.Preferred carrier materials include mannitol. Preferred glides comprise colloidal silica. Such dosage forms are useful in the treatment of pulmonary diseases, such as idiopathic pulmonary fibrosis, sarcoidosis, and tissue damage induced by respiratory viruses.

There is provided pharmaceutical compounds of formula I,wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have meanings given in the description, which compounds are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

A method of treating COPD, Asthma, Pneumonia, Bronchitis, Cystic Fibrosis, Pulmonary Edema, Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis and PAH in a patient. One embodiment includes administering a vasodilator prostacyclin analogue, such as Beraprost or Iloprost, separately or together with a form of Diethylcarbamazine or Zileuton. Other embodiments may include fluvoxamine. The vasodilator prostacyclin analogue is inhaled. Diethylcarbamazine / Zileuton is inhaled into the lung or administered orally or intravenously. Other embodiments include fluvoxamine. This treatment reduces the progression of the disease, reduces life-threatening exacerbations, and improves the quality of life. The treatment is also for COPD patients with eosinophilia who are incompletely treated with steroids and addresses steroid-unresponsive disease components of COPD including pulmonary hypertension and intravascular inflammation and bronchiectasis. The treatment may include a PDE4 inhibitor and current treatments with existing steroids and beta-adrenergic receptor agonists and / or muscarinic receptor blockers. The treatment is also for ARDS and COVID-19.

Disclosed is use of reishi spore oil in the preparation of a drug for preventing and treating nodular diseases. Animal experiments show that reishi spore oil has the effect of significantly inhibiting the formation and development of benign granulomatous nodules in the lungs of mice, and also possesses good safety. The reishi spore oil can be used for preparing a drug for preventing and treating the formation and development of pulmonary nodules. The reishi spore oil comprises one or more components of triglyceride, ergosterol, and vitamin E; and the reishi polysaccharide ingredient is not detected.